NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Altay Therapeutics

Altay Therapeutics

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.altaytherapeutics.com/

Last Round

Grant

Sep 1, 2023

Est. Valuation

$2.14M

Total Funding Raised

$3.45M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Altay Therapeutics is a biotechnology company that develops small molecule therapeutics targeting transcription factors to treat chronic inflammatory diseases, neuromuscular disorders, and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Application

Keywords

drug discoverysmall molecule inhibitorstranscription factorscomputational biologyallosteric binding sitesai drug discoveryundruggable targetsbiotechsmall business innovation researchSBIRstructural dynamicsin silico drug designtherapeutic pipelineoncology therapeuticsneuromuscular disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Altay Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Altay Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Altay Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 1, 2023
GrantJul 11, 2023
SeedSep 21, 2022
AcceleratorMar 16, 2020

Key People

Founding team and executive leadership

Osman Nidai Ozes

Founder And Chief Scientific Officer

Founding Team

Ali Ozes

Founder And CEO

Founding Team

Altay Therapeutics Investors

Notable investors and investment history

Altay Therapeutics investors
InvestorRounds
NIH RADxGrant
Solve FSHDGrant, Seed
Y CombinatorAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors increased 59% MoM.

  • Apr 21, 2026

    Monthly visitors increased 621% MoM, reaching 1.2K.

Altay Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Altay Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Altay Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range6
Year Founded2019
Last FundingSep 1, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.